A phase 3 PROTEUS substudy published in European Urology reports that perioperative apalutamide plus hormone therapy around ...
An international phase III substudy found that apalutamide, androgen-deprivation therapy and surgery reduced the risk of ...
An international phase 3 clinical trial that treated patients with high-risk localized and locally advanced prostate cancer ...
An international phase 3 clinical trial that treated patients with high-risk localized and locally advanced prostate cancer ...
An international phase 3 clinical trial that treated patients with high-risk localized and locally advanced prostate cancer ...
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (64.1%): drugs i ...
New substudy results showed a 51% lower estimated risk of metastasis or death over time with perioperative apalutamide plus ...
Briganti and colleagues concluded that, together with the main PROTEUS study, the substudy supports 1-year perioperative apalutamide plus ADT as a treatment option for patients with high-risk ...
Today we highlight a study that found benefits of wearable glucose monitoring devices for all patients with diabetes, regardless of insulin dependence. We also report on a positive trial of a J&J ...
Welltica+ on MSN
New drug could prevent 70% of muscle loss linked to Ozempic
An experimental drug protected most of the muscle people typically lose while taking a GLP-1 drug.
Revascularization of a hypoperfused hemisphere in chronic, asymptomatic ICA stenosis did not reverse cognitive dysfunction.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results